Shereen Ezzat

List of Publications by Year in Descending Order

283 papers	11,638 citations	57 h-index	99 g-index
300 ext. papers	12,906 ext. citations	6 avg, IF	6.3 L-index

#	Paper	IF	Citations
283	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.. *Endocrine Pathology*, **2022**, 33, 115-154	4.2	18
282	The Management of Neuro-Endocrine Neoplasms **2021**, 461-469		2
281	The Diagnosis of Neuroendocrine Neoplasms **2021**, 15-27		1
280	Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease. *Frontiers in Endocrinology*, **2021**, 12, 620005	5.7	2
279	Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. *Modern Pathology*, **2021**, 34, 1634-1650	9.8	7
278	An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3
277	Prolactin, a potential biomarker for chronic GVHD activity. *European Journal of Haematology*, **2021**, 106, 158-164	3.8	1
276	Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors. *World Neurosurgery*, **2021**, 146, e341-e350	2.1	5
275	Epigenetics of Pituitary Cell Growth and Survival **2021**, 93-103		
274	Pathology of pituitary growth hormone excess **2021**, 17-37		
273	The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research. *Endocrine Pathology*, **2021**, 32, 415-417	4.2	2
272	Ultrasound in active surveillance for low-risk papillary thyroid cancer: imaging considerations in case selection and disease surveillance. *Insights Into Imaging*, **2021**, 12, 130	5.6	0
271	Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer. *Oral Oncology*, **2021**, 121, 105477	4.4	1
270	Hypothalamic hormone-producing tumors. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2021**, 181, 67-74	3	2
269	Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?. *Endocrine Pathology*, **2021**, 32, 3-16	4.2	5
268	Response to Miyauchi re: "A Prospective Mixed-Methods Study of Decision Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer". *Thyroid*, **2020**, 30, 1542-1543	6.2	
267	A Prospective Mixed-Methods Study of Decision-Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer. *Thyroid*, **2020**, 30, 999-1007	6.2	22

266	Management of Small Bowel Neuroendocrine Tumors. *Cancers*, **2019**, 11,	6.6	11
265	An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. *Endocrine Pathology*, **2019**, 30, 118-127	4.2	28
264	PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE. *Endocrine Practice*, **2019**, 25, 379-393	3.2	21
263	Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. *Annals of Surgical Oncology*, **2019**, 26, 2533-2539	3.1	9
262	Treatment Options for Pancreatic Neuroendocrine Tumors. *Cancers*, **2019**, 11,	6.6	33
261	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. *British Journal of Cancer*, **2019**, 120, 1113-1119	8.7	42
260	Molecular Predictors of Clinical Behavior in Pituitary Adenohypophysial Tumors. *Contemporary Endocrinology*, **2019**, 155-172	0.3	
259	Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis. *Journal of Cancer Survivorship*, **2019**, 13, 231-243	5.1	7
258	Hypothalamic Vasopressin-Producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease. *American Journal of Surgical Pathology*, **2019**, 43, 251-260	6.7	22
257	A Systematic Review and Meta-Analysis of Patient Preferences for Combination Thyroid Hormone Treatment for Hypothyroidism. *Frontiers in Endocrinology*, **2019**, 10, 477	5.7	15
256	Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. *Clinical Genetics*, **2019**, 96, 461-467	4	7
255	A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology. *Endocrine Pathology*, **2019**, 30, 201-218	4.2	18
254	The Clinicopathological Spectrum of Parathyroid Carcinoma. *Frontiers in Endocrinology*, **2019**, 10, 731	5.7	12
253	The Clinicopathological Spectrum of Acromegaly. *Journal of Clinical Medicine*, **2019**, 8,	5.1	23
252	Re: Quality of life and symptom impact of thyroid cancer: A cross-sectional survey of Canadian patients. *Surgery*, **2019**, 166, 948-949	3.6	0
251	Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin. *Endocrine Pathology*, **2018**, 29, 15-20	4.2	4
250	Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. *Molecular and Cellular Endocrinology*, **2018**, 469, 70-76	4.4	16
249	The epigenetic landscape of differentiated thyroid cancer. *Molecular and Cellular Endocrinology*, **2018**, 469, 3-10	4.4	20

248	Primary mediastinal paraganglioma associated with a familial variant in the succinate dehydrogenase B subunit gene. *Journal of Surgical Oncology*, **2018**, 117, 160-162	2.8	4
247	The retrotransposon gag domain containing protein Rgag4 is an Ikaros target in the pituitary. *Molecular and Cellular Endocrinology*, **2018**, 461, 188-193	4.4	3
246	A large and aggressive fibromatosis in the axilla: a rare case report and review of the literature. *OncoTargets and Therapy*, **2018**, 11, 3179-3184	4.4	4
245	Symptom burden in adults with thyroid cancer. *Psycho-Oncology*, **2018**, 27, 2517-2519	3.9	1
244	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. *Nature Genetics*, **2018**, 50, 979-989	36.3	90
243	Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. *AACE Clinical Case Reports*, **2018**, 4, e289-e293	0.7	
242	Is Hypothalamic Oxytocin Dispensable for Parturition?. *AACE Clinical Case Reports*, **2018**, 4, e437-e438	0.7	
241	Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion. *Frontiers in Endocrinology*, **2018**, 9, 641	5.7	11
240	Pituitary Tumors; Diagnosis and Treatment **2018**, 257-257		
239	A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. *Thyroid*, **2018**, 28, 1662-1673	6.2	33
238	The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. *Journal of Clinical Medicine*, **2018**, 7,	5.1	71
237	Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. *Endocrine Pathology*, **2018**, 29, 332-338	4.2	15
236	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 340-352	4	64
235	Molecular Pathogenesis of Pituitary Tumors **2017**, 165-175		
234	Pituitary acromegaly: not one disease. *Endocrine-Related Cancer*, **2017**, 24, C1-C4	5.7	27
233	Pituitary Adenomas Presenting as Sinonasal or Nasopharyngeal Masses: A Case Series Illustrating Potential Diagnostic Pitfalls. *American Journal of Surgical Pathology*, **2017**, 41, 525-534	6.7	23
232	Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature. *OncoTargets and Therapy*, **2017**, 10, 5459-5462	4.4	8
231	Ikaros and its interacting partner CtBP target the metalloprotease ADAMTS10 to modulate pituitary cell function. *Molecular and Cellular Endocrinology*, **2017**, 439, 126-132	4.4	4

230	FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. *Oncotarget*, **2017**, 8, 3481-3494	3.3	13
229	NG2 targets tumorigenic Rb inactivation in Pit1-lineage pituitary cells. *Endocrine-Related Cancer*, **2016**, 23, 445-56	5.7	6
228	Unmet Information Needs of Low-Risk Thyroid Cancer Survivors. *Thyroid*, **2016**, 26, 474-5	6.2	11
227	Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. *Expert Review of Endocrinology and Metabolism*, **2016**, 11, 149-162	4.1	33
226	Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. *Modern Pathology*, **2016**, 29, 131-42	9.8	86
225	High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor. *Oncotarget*, **2016**, 7, 19948-59	3.3	11
224	PANCREATIC INCIDENTALOMAS: IS IT NET OR NOT?. *Endocrine Practice*, **2016**, 22, 895-6	3.2	1
223	Thyroid Cancer Incidence and Endocrinologist Access: A Regional Data Analysis from Ontario, Canada. *Endocrine Practice*, **2016**, 22, 642-3	3.2	
222	Exploring the Life Impact of Treated Low-Risk Thyroid Cancer. *Endocrine Practice*, **2016**, 22, 513-4	3.2	4
221	A detailed spatial analysis on contrasting cancer incidence patterns in thyroid and lung cancer in Toronto women. *BMC Public Health*, **2016**, 16, 950	4.1	8
220	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. *Cancer Treatment Reviews*, **2016**, 47, 32-45	14.4	57
219	Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. *Endocrine Pathology*, **2016**, 27, 97-103	4.2	8
218	Concerns of low-risk thyroid cancer survivors. *Acta Oncologica*, **2016**, 55, 1252-1253	3.2	7
217	Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2015**, 466, 727-32	5.1	30
216	Exploring the relationship between patients' information preference style and knowledge acquisition process in a computerized patient decision aid randomized controlled trial. *BMC Medical Informatics and Decision Making*, **2015**, 15, 48	3.6	5
215	Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial. *Cancer*, **2015**, 121, 3717-26	6.4	11
214	Cancer-related worry in Canadian thyroid cancer survivors. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 977-85	5.6	54
213	A systematic review of randomized controlled trials for management of persistent post-treatment fatigue in thyroid cancer survivors. *Thyroid*, **2015**, 25, 198-210	6.2	9

212	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension. *Trials*, **2015**, 16, 302	2.8	3
211	Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. *Turk Patoloji Dergisi*, **2015**, 31 Suppl 1, 4-17	0.6	11
210	The role of diabetes in acromegaly associated neoplasia. *PLoS ONE*, **2015**, 10, e0127276	3.7	16
209	Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP **2015**, 125-139		1
208	Retraction. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. *Journal of Clinical Investigation*, **2015**, 125, 3303	15.9	1
207	Growth patterns of pituitary adenomas and histopathological correlates. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 1330-8	5.6	31
206	AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease. *Endocrine Practice*, **2014**, 20, 608-16	3.2	7
205	FGFR4 polymorphic variants modulate phenotypic features of Cushing disease. *Molecular Endocrinology*, **2014**, 28, 525-33		16
204	Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. *Modern Pathology*, **2014**, 27, 1050-62	9.8	11
203	Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review. *Endocrinology and Metabolism Clinics of North America*, **2014**, 43, 475-94	5.5	19
202	Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. *Endocrine Practice*, **2014**, 20, e145-50	3.2	11
201	The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. *Endocrine-Related Cancer*, **2014**, 21, R331-44	5.7	44
200	Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. *Archives of Pathology and Laboratory Medicine*, **2014**, 138, 182-8	5	44
199	Temporal trends in thyroid cancer incidence in California-letter. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 2609	4	2
198	Epigenetics of Pituitary Cell Growth and Survival **2014**, 101-110		
197	Managing newly diagnosed thyroid cancer. *Cmaj*, **2014**, 186, 269-75	3.5	4
196	Functional cardiac paraganglioma associated with a rare SDHC mutation. *Endocrine Pathology*, **2014** , 25, 315-20	4.2	15
195	Genomic approaches to problems in pituitary neoplasia. *Endocrine Pathology*, **2014**, 25, 209-13	4.2	9

194	Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel-Lindau disease. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2013**, 463, 593-7	5.1	23
193	The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. *Endocrine Pathology*, **2013**, 24, 191-8	4.2	28
192	The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes. *Cell Metabolism*, **2013**, 17, 929-940	24.6	22
191	Signs and Symptoms of Pituitary Disease **2013**, 13-20		
190	Secondary Adrenal Insufficiency **2013**, 32-46		
189	Adult Growth Hormone Deficiency **2013**, 47-54		
188	Pituitary Carcinoma **2013**, 55-58		
187	Empty Sella Syndrome **2013**, 77-86		
186	Familial Pituitary Adenomas **2013**, 87-110		
185	Follicle Stimulating Hormone and Luteinizing Hormone Secreting Tumors **2013**, 111-119		
184	Hypopituitarism **2013**, 120-129		
183	Clinically Nonfunctioning Pituitary Adenomas **2013**, 130-137		
182	Rathke Cleft Cysts **2013**, 146-152		
181	Thyroid Hormone Deficiency **2013**, 153-158		
180	Thyroid Stimulating Hormone Secreting Tumor **2013**, 159-166		
179	Pituitary Disorders Specific Issues for Women **2013**, 167-178		
178	Hypogonadism and Male Sexual Function **2013**, 179-192		
177	Pituitary Disorders Specific to Children **2013**, 193-203		

176	Pituitary Endocrine Function Testing **2013**, 213-224		
175	Surgical Management of Pituitary Disorders **2013**, 243-254		
174	Medical Management of Pituitary Adenomas **2013**, 225-242		
173	Stereotactic Radiosurgery for Pituitary Adenomas **2013**, 255-264		
172	Hormone Replacement Therapy **2013**, 265-276		
171	Complications of Pituitary Disease **2013**, 277-290		
170	Living with Pituitary Disease **2013**, 301-310		
169	Research and Clinical Trials **2013**, 311-322		
168	Fundamentals of Pituitary Pathology **2013**, 323-332		
167	The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation. *Thyroid*, **2013**, 23, 246-7	6.2	7
166	Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior. *Cancer Medicine*, **2013**, 2, 701-11	4.8	25
165	Emerging trends in the diagnosis and treatment of acromegaly in Canada. *Clinical Endocrinology*, **2013**, 79, 79-85	3.4	24
164	Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly. *PLoS ONE*, **2013**, 8, e73543	3.7	8
163	Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. *PLoS ONE*, **2013**, 8, e61538	3.7	23
162	Biomarkers of aggressive pituitary adenomas. *Journal of Molecular Endocrinology*, **2012**, 49, R69-78	4.5	105
161	The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-B signaling. *Molecular and Cellular Biology*, **2012**, 32, 4662-73	4.8	19
160	Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. *Clinical Endocrinology*, **2012**, 76, 264-71	3.4	51
159	Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 1745-51	5.6	92

158	FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. *Cancer Research*, **2012**, 72, 2017-27	10.1	23
157	CtBP1 interacts with Ikaros and modulates pituitary tumor cell survival and response to hypoxia. *Molecular Endocrinology*, **2012**, 26, 447-57		21
156	The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. *Cancer Research*, **2012**, 72, 5683-91	10.1	41
155	Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. *Laboratory Investigation*, **2011**, 91, 147-56	5.9	12
154	A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. *Clinical Cancer Research*, **2011**, 17, 2385-94	12.9	58
153	The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. *PLoS Genetics*, **2011**, 7, e1002400	6	56
152	Protocol for the examination of specimens from patients with primary pituitary tumors. *Archives of Pathology and Laboratory Medicine*, **2011**, 135, 640-6	5	28
151	Chromatin remodeling and histone modifications in pituitary tumors. *Molecular and Cellular Endocrinology*, **2010**, 326, 66-70	4.4	15
150	Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. *American Journal of Pathology*, **2010**, 176, 2333-43	5.8	15
149	Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. *American Journal of Pathology*, **2010**, 177, 2860-9	5.8	8
148	Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. *Thyroid*, **2010**, 20, 1129-38	6.2	56
147	GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules. *Endocrine Pathology*, **2010**, 21, 250-2	4.2	1
146	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer--a randomized controlled trial. *Trials*, **2010**, 11, 81	2.8	12
145	Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. *Cancer Research*, **2009**, 69, 2739-47	10.1	81
144	Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. *Molecular Endocrinology*, **2009**, 23, 1397-405		25
143	Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. *Endocrine-Related Cancer*, **2009**, 16, 455-66	5.7	16
142	Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. *Journal of Pathology*, **2009**, 218, 232-40	9.4	11
141	A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. *Clinical Endocrinology*, **2009**, 71, 549-57	3.4	96

140	The pathogenesis of pituitary tumors. *Annual Review of Pathology: Mechanisms of Disease*, **2009**, 4, 97-126	34	185
139	Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 5-9	5.6	128
138	Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. *Thyroid*, **2009**, 19, 451-7	6.2	244
137	The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study. *PLoS ONE*, **2009**, 4, e4191	3.7	47
136	A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. *Clinical and Investigative Medicine*, **2009**, 32, E265	0.9	6
135	A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. *Clinical Endocrinology*, **2008**, 68, 610-7	3.4	63
134	A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. *Clinical Endocrinology*, **2008**, 69, 479-90	3.4	129
133	Mice lacking the transcription factor Ikaros display behavioral alterations of an anti-depressive phenotype. *Experimental Neurology*, **2008**, 211, 107-14	5.7	11
132	Epigenetic dysregulation in thyroid neoplasia. *Endocrinology and Metabolism Clinics of North America*, **2008**, 37, 389-400, ix	5.5	24
131	The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. *Cancer Research*, **2008**, 68, 8104-12	10.1	108
130	Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. *Clinical Cancer Research*, **2008**, 14, 1984-96	12.9	62
129	The emerging role of the Ikaros stem cell factor in the neuroendocrine system. *Journal of Molecular Endocrinology*, **2008**, 41, 45-51	4.5	17
128	Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. *Cancer Research*, **2008**, 68, 6688-97	10.1	46
127	Ikaros modulates cholesterol uptake: a link between tumor suppression and differentiation. *Cancer Research*, **2008**, 68, 3715-23	10.1	23
126	Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 3610-7	5.6	36
125	Epigenetic control in pituitary tumors. *Endocrine Journal*, **2008**, 55, 951-7	2.9	25
124	Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. *Endocrine Practice*, **2008**, 14, 175-84	3.2	17
123	Acromegaly: re-thinking the cancer risk. *Reviews in Endocrine and Metabolic Disorders*, **2008**, 9, 41-58	10.5	93

122	Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. *Leukemia Research*, **2008**, 32, 1480-2	2.7	11
121	Chromatin remodeling: the interface between extrinsic cues and the genetic code?. *Clinical and Investigative Medicine*, **2008**, 31, E272-81	0.9	1
120	Clinical predictors of advanced sellar masses. *Endocrine Practice*, **2007**, 13, 609-14	3.2	2
119	Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology. *Endocrine Pathology*, **2007**, 18, 37-41	4.2	10
118	AIP Mutations are not identified in patients with sporadic pituitary adenomas. *Endocrine Pathology*, **2007**, 18, 76-8	4.2	25
117	Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. *Cancer Research*, **2007**, 67, 5461-70	10.1	60
116	Is autoimmune pituitary disease underdiagnosed?. *Nature Clinical Practice Endocrinology and Metabolism*, **2007**, 3, 678-9		
115	A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. *Cancer Research*, **2007**, 67, 7505-11	10.1	61
114	Ikaros is regulated through multiple histone modifications and deoxyribonucleic acid methylation in the pituitary. *Molecular Endocrinology*, **2007**, 21, 1205-15		14
113	Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. *Thyroid*, **2007**, 17, 1277-88	6.2	106
112	Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. *Thyroid*, **2007**, 17, 1235-42	6.2	12
111	The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. *Clinical Cancer Research*, **2007**, 13, 4713-20	12.9	41
110	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. *Blood*, **2007**, 110, 4047-54	2.2	48
109	Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. *Human Pathology*, **2007**, 38, 1810-8	3.7	36
108	Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. *American Journal of Pathology*, **2007**, 170, 1618-28	5.8	60
107	Comparison of body composition assessment methods in patients with human immunodeficiency virus-associated wasting receiving growth hormone. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2952-9	5.6	7
106	The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. *Endocrine Reviews*, **2006**, 27, 287-317	27.2	140
105	Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. *Molecular Endocrinology*, **2006**, 20, 2976-86		35

104	The cost of medical care for the acromegalic patient. *Neuroendocrinology*, **2006**, 83, 139-44	5.6	15
103	An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 2214-9	11.5	39
102	Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. *Molecular Endocrinology*, **2006**, 20, 2965-75		39
101	Dopaminergic resistant prolactinomas in the peripubertal population. *Journal of Pediatric Endocrinology and Metabolism*, **2006**, 19, 951-3	1.6	9
100	Mechanisms of disease: The pathogenesis of pituitary tumors. *Nature Clinical Practice Endocrinology and Metabolism*, **2006**, 2, 220-30		72
99	Microadenomatosis of the pancreas in von Hippel-Lindau disease. *American Journal of Surgical Pathology*, **2006**, 30, 1630; author reply 1630-1	6.7	7
98	Pathogenetic mechanisms in thyroid follicular-cell neoplasia. *Nature Reviews Cancer*, **2006**, 6, 292-306	31.3	674
97	Canadian consensus guidelines for the diagnosis and management of acromegaly. *Clinical and Investigative Medicine*, **2006**, 29, 29-39	0.9	8
96	Circulating and synovial levels of IGF-I, cytokines, physical function and anthropometry differ in women awaiting total knee arthroplasty when compared to men. *Journal of Orthopaedic Research*, **2005**, 23, 397-405	3.8	14
95	Genetics and proteomics of pituitary tumors. *Endocrine*, **2005**, 28, 43-7		28
94	Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting. *American Journal of Physiology - Endocrinology and Metabolism*, **2005**, 289, E494-503	6	19
93	Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. *Endocrinology*, **2005**, 146, 1145-53	4.8	104
92	The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. *Molecular Endocrinology*, **2005**, 19, 1004-11		36
91	The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 6290-5	5.6	139
90	1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. *Molecular Endocrinology*, **2005**, 19, 2349-57		42
89	Ikaros integrates endocrine and immune system development. *Journal of Clinical Investigation*, **2005**, 115, 1021-1029	15.9	37
88	Ikaros integrates endocrine and immune system development. *Journal of Clinical Investigation*, **2005**, 115, 1021-9	15.9	15
87	Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. *Clinical Cancer Research*, **2005**, 11, 1336-41	12.9	56

86	Pharmacological options in the treatment of acromegaly. *Current Opinion in Investigational Drugs*, **2005**, 6, 1023-7		0
85	AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. *Endocrine Practice*, **2004**, 10, 213-25	3.2	72
84	Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. *Endocrinology*, **2004**, 145, 5840-6	4.8	52
83	Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 5124-31	5.6	12
82	Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. *Molecular Endocrinology*, **2004**, 18, 2543-52		71
81	Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage. *Clinical Cancer Research*, **2004**, 10, 6750-8	12.9	16
80	Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells. *Laboratory Investigation*, **2004**, 84, 1571-80	5.9	12
79	Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions. *Endocrine Pathology*, **2004**, 15, 141-8	4.2	38
78	The prevalence of pituitary adenomas: a systematic review. *Cancer*, **2004**, 101, 613-9	6.4	885
77	Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 1904-11	5.6	56
76	Molecular basis of pituitary development and cytogenesis. *Frontiers of Hormone Research*, **2004**, 32, 1-19	3.5	36
75	Pharmacological approach to the treatment of acromegaly. *Neurosurgical Focus*, **2004**, 16, E3	4.2	1
74	Current views on pathogenesis of pituitary tumors. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2004**, 11, 281-286		
73	Pituitary Tumors, Molecular Pathogenesis **2004**, 681-686		
72	Growth factors and their receptors in the genesis and treatment of thyroid cancer. *Cancer Treatment and Research*, **2004**, 122, 121-9	3.5	1
71	Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. *Journal of Biological Chemistry*, **2003**, 278, 19597-602	5.4	37
70	Pituitary tumor pathogenesis--the hunt for novel candidate genes continues. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 5116-8	5.6	7
69	Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 5734-8	5.6	24

68	Management of Lesions of the Pituitary Stalk and Hypothalamus **2003**, 13, 38-51		13
67	Controversies in papillary microcarcinoma of the thyroid. *Endocrine Pathology*, **2003**, 14, 183-91	4.2	67
66	Myostatin is a skeletal muscle target of growth hormone anabolic action. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 5490-6	5.6	102
65	Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5Q fibroblast growth factor receptor-4 promoter. *American Journal of Pathology*, **2003**, 163, 1177-84	5.8	69
64	Controversies in papillary microcarcinoma of the thyroid **2003**, 14, 183		8
63	Diagnosis and management of hyperprolactinemia. *Cmaj*, **2003**, 169, 575-81	3.5	46
62	Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. *Brain Pathology*, **2002**, 12, 412-9	6	28
61	Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. *Clinical Endocrinology*, **2002**, 56, 351-8	3.4	21
60	The pathogenesis of pituitary tumours. *Nature Reviews Cancer*, **2002**, 2, 836-49	31.3	276
59	Medical management of pituitary adenomas: structural and ultrastructural changes. *Pituitary*, **2002**, 5, 133-9	4.3	14
58	Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1814-8	5.6	113
57	Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1810-3	5.6	78
56	Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. *Molecular Endocrinology*, **2002**, 16, 1069-78		35
55	Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. *American Journal of Physiology - Endocrinology and Metabolism*, **2002**, 283, E490-5	6	9
54	Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. *American Journal of Pathology*, **2002**, 160, 511-9	5.8	74
53	Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. *Journal of Clinical Investigation*, **2002**, 109, 69-78	15.9	124
52	The role of hormones, growth factors and their receptors in pituitary tumorigenesis. *Brain Pathology*, **2001**, 11, 356-70	6	46
51	Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly. *Clinical Endocrinology*, **2001**, 55, 135-40	3.4	19

50	Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. *Clinical Endocrinology*, **2001**, 55, 549-56	3.4	37
49	Longitudinal assessment of economic burden and clinical outcomes in acromegaly. *Endocrine Practice*, **2001**, 7, 170-80	3.2	19
48	The Pathophysiology of Pituitary Tumors. *Seminars in Neurosurgery*, **2001**, 12, 261-272		
47	The Classification of Pituitary Tumors: An Update. *Seminars in Neurosurgery*, **2001**, 12, 273-288		1
46	Physical performance in growth hormone- deficient adults. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 1839-40	5.6	1
45	The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production. *Molecular Endocrinology*, **2001**, 15, 589-99		50
44	Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 2187-90	5.6	150
43	The spectrum and significance of primary hypophysitis. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 1048-53	5.6	155
42	Immunohistochemical diagnosis of papillary thyroid carcinoma. *Modern Pathology*, **2001**, 14, 338-42	9.8	265
41	A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells. *Biochemical and Biophysical Research Communications*, **2001**, 287, 60-5	3.4	33
40	Molecular basis off hurthle cell papillary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 878-82	5.6	99
39	Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. *American Journal of Pathology*, **2000**, 156, 1009-15	5.8	55
38	Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 4570-7	5.6	85
37	Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 3972-82	5.6	190
36	Molecular determinants of pituitary cytodifferentiation. *Pituitary*, **1999**, 1, 159-68	4.3	42
35	Clinicopathological variations in cushing's syndrome. *Endocrine Pathology*, **1999**, 10, 165-71	4.2	2
34	Oncogene profile of papillary thyroid carcinoma. *Surgery*, **1999**, 125, 46-52	3.6	73
33	Autoimmune Hypophysitis **1999**, 337-348		6

32	Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. *Clinical Endocrinology*, **1998**, 49, 629-37	3.4	18
31	Psychological features of acromegaly. *Psychotherapy and Psychosomatics*, **1998**, 67, 147-53	9.4	35
30	Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2291-5	5.6	61
29	The MEN-1 gene is rarely down-regulated in pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 3210-2	5.6	53
28	Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 4116-22	5.6	215
27	The cytogenesis and pathogenesis of pituitary adenomas. *Endocrine Reviews*, **1998**, 19, 798-827	27.2	251
26	Altered expression of fibroblast growth factor receptors in human pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 1160-6	5.6	104
25	Acromegaly. *Endocrinology and Metabolism Clinics of North America*, **1997**, 26, 703-23	5.5	21
24	Autoimmune hypophysitis. *Trends in Endocrinology and Metabolism*, **1997**, 8, 74-80	8.8	32
23	Cushing's Syndrome from an Ectopic Pituitary Adenoma with Peliosis: A Histological, Immunohistochemical, and Ultrastructural Study and Review of the Literature. *Endocrine Pathology*, **1997**, 8, 65-74	4.2	44
22	The c-erbB-2/neu proto-oncogene in human pituitary tumours. *Clinical Endocrinology*, **1997**, 46, 599-606	3.4	38
21	Prevalence of activating ras mutations in morphologically characterized thyroid nodules. *Thyroid*, **1996**, 6, 409-16	6.2	90
20	Basic Fibroblast Growth Factor Expression by Two Prolactin and Thyrotropin-Producing Pituitary Adenomas. *Endocrine Pathology*, **1995**, 6, 125-134	4.2	53
19	In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. *European Journal of Endocrinology*, **1995**, 133, 686-90	6.5	92
18	A prospective multicenter octreotide dose response study in the treatment of acromegaly. *Journal of Endocrinological Investigation*, **1995**, 18, 364-9	5.2	18
17	Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. *Journal of Clinical Pharmacology*, **1995**, 35, 59-71	2.9	10
16	Clonality of thyroid nodules in sporadic goiter. *Diagnostic Molecular Pathology*, **1995**, 4, 113-21		101
15	Thyroid Incidentalomas. *Archives of Internal Medicine*, **1994**, 154, 1838		384

14	Effect of octreotide on glucose tolerance in acromegaly. *European Journal of Endocrinology*, **1994**, 130, 581-6	6.5	55
13	[13C]NMR studies of the effect of the somatostatin analogue octreotide on hepatic glycogenesis and glycogenolysis. *Peptides*, **1994**, 15, 1223-7	3.8	4
12	Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. *Cancer*, **1993**, 71, 66-70	6.4	27
11	Octreotide treatment of acromegaly. A randomized, multicenter study. *Annals of Internal Medicine*, **1992**, 117, 711-8	8	184
10	Endocrine applications of the somatostatin analogue octreotide (Sandostatin). *Metabolism: Clinical and Experimental*, **1992**, 41, 34-8	12.7	9
9	Living with Acromegaly. *Endocrinology and Metabolism Clinics of North America*, **1992**, 21, 753-760	5.5	14
8	Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **1991**, 73, 441-3	5.6	39
7	Clinical review 18: Are patients with acromegaly at increased risk for neoplasia?. *Journal of Clinical Endocrinology and Metabolism*, **1991**, 72, 245-9	5.6	118
6	Colon polyps in acromegaly. *Annals of Internal Medicine*, **1991**, 114, 754-5	8	62
5	Mechanisms of pituitary tumorigenesis652-668		
4	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas		23
3	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary		11
2	General Psychological and Psychosocial Effects of Pituitary Disorders291-299		
1	Prolactinoma138-145		